Pharmala Biotech : Offering Document under the Listed Issuer Financing Exemption

The securities offered under this offering document under the Listed Issuer Financing Exemption have not been, and will not be, registered under the United States Securities Act of 1933, as... | June 13, 2023

Related Keywords

Toronto ,Ontario ,Canada ,Australia ,United Kingdom ,Monash ,South Australia ,California ,United States ,Sydney ,New South Wales ,Canadian ,Australian , ,Emyria Ltd ,Research Grant ,Clinical Psychedelic Lab At Monash University ,Vitura Health ,University Of Sydney ,Psilo Scientific Ltd ,Cortexa Pty Ltd ,Awakn Ls Europe Holdings ,Acceleration Press ,Pharmala Biotech Holdings Inc ,Drug Administration ,Access Program Authorization ,Partner To Awakn Ls Europe Holdings ,Psilo Scientific Health Canada ,Australian Therapeutic Goods Agency ,Therapeutics Ltd ,Ontario Centre For Innovation ,Canadian Securities Exchange ,Laboratories Inc ,University Of Windsor ,Clinical Psychedelic Lab ,Master Services Agreement ,University Of California ,Incannex Healthcare Ltd ,Filament Health Corp ,Drug Administration Approval ,University Of Arkansas School For Medical Sciences ,Ontario Centre For Innovation The Research Grant ,National Instrument ,Health Canada ,Listed Issuer Financing Exemption ,United States Securities Act ,Offering Document ,Listed Issuer Financing ,Each Warrant ,Common Share ,Closing Date ,Warrant Acceleration Press ,Common Shares ,Revive Therapeutics Ltd ,Pharmala Trademark ,Laneo Trademark ,Intellectual Property ,Vitura Joint Venture ,Holdings Limited ,Awakn Agreement ,Regulatory Changes ,Revive Therapeutics ,Emyria Purchase Order ,Australian Government ,Application Published ,Patent Cooperation Treaty ,Novel Chemical Entities ,Arkansas School ,Medical Sciences ,Services Agreement ,Filament Health ,Psilo Scientific ,Monash University ,Incannex Healthcare ,Vitura Health Limited ,Cortexa Pty ,Joint Venture Agreement ,Joint Venture ,Vitura Joint ,C Crest Laboratories Inc ,Ontario Centre ,Clinical Trial Use ,